Novartis Pays $50m Upfront Cash for License and Stock in Mesoblast to Access Mesenchymal Stromal Cells Regenerative Therapy Platform
Novartis recently inked an exclusive worldwide license and collaboration agreement with regenerative therapy venture Mesoblast to develop, commercialize and manufacture […]